Stock CASI CASI PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

CASI Pharmaceuticals, Inc. Stock

Equities

CASI

KYG1933S1012

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-15 pm EDT 		5-day change 1st Jan Change
3.27 USD +3.15% Intraday chart for CASI Pharmaceuticals, Inc. +23.86% -54.33%
May. 15 Sector Update: Health Care Stocks Advance in Afternoon Trading MT
May. 15 CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials (USD)

Sales 2024 * 19.8M Sales 2025 * 46.48M Capitalization 42.48M
Net income 2024 * -35M Net income 2025 * -33M EV / Sales 2024 * 2.15 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.91 x
P/E ratio 2024 *
-1.28 x
P/E ratio 2025 *
-1.54 x
Employees 176
Yield 2024 *
-
Yield 2025 *
-
Free-Float 50.99%
More Fundamentals * Assessed data

Chart CASI Pharmaceuticals, Inc.

Dynamic Chart

Latest news about CASI Pharmaceuticals, Inc.

Sector Update: Health Care Stocks Advance in Afternoon Trading MT
CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study MT
CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug Application for CID-103 in Immune Thrombocytopenia CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q1 Revenue $3.4M, vs. Street Est of $12M MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Midday Gainers MT
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell MT
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday MT
Top Premarket Gainers MT
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China CI
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd CI
Casi Pharmaceuticals Announces First Dose of Folotyn in China CI
CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer CI
CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer CI
More news

Analyst Recommendations on CASI Pharmaceuticals, Inc.

HC Wainwright Raises Price Target on CASI Pharmaceuticals to $12 From $10, Keeps Buy Rating MT
BTIG Adjusts CASI Pharmaceuticals' Price Target to $10 From $21, Keeps Buy Rating MT
CORRECTION : BTIG Lowers CASI Pharmaceuticals' Price Target to $21 From $40, Buy Rating Kept MT
HC Wainwright Lowers CASI Pharmaceuticals' Price Target to $12 From $30, Buy Rating Maintained MT
Oppenheimer Adjusts CASI Pharmaceuticals' Price Target to $35 From $6 After Reverse Stock Split, Maintains Outperform Rating MT
More recommendations

Press releases CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) PR
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS PR
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS PR
CASI Pharmaceuticals : Received Emergency Relief in connection with the Dispute with Juventas - Form 6-K PU
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS PR
More press releases

Quotes and Performance

1 day+3.15%
1 week+23.86%
Current month+38.91%
1 month+30.80%
3 months-45.23%
6 months-24.83%
Current year-54.33%
More quotes

Highs and lows

1 week
2.36
Extreme 2.36
3.54
1 month
2.05
Extreme 2.05
3.54
Current year
2.05
Extreme 2.05
8.19
1 year
1.85
Extreme 1.85
8.48
3 years
1.45
Extreme 1.45
17.75
5 years
1.45
Extreme 1.45
39.00
10 years
1.45
Extreme 1.45
88.92
More quotes

Managers and Directors - CASI Pharmaceuticals, Inc.

Managers TitleAgeSince
Wei Wu He CEO
 Chief Executive Officer 59 19-04-01
Wei Zhang DFI
 Director of Finance/CFO 64 18-08-31
Chun Hua Wang COO
 Chief Operating Officer 52 16-12-31
Members of the board TitleAgeSince
Wei Wu He CEO
 Chief Executive Officer 59 19-04-01
Yue Wu BRD
 Director/Board Member 62 13-03-31
Zhen Bo Su BRD
 Director/Board Member 48 23-03-20
More insiders

Quotes

Date Price Change Volume
24-05-15 3.27 +3.15% 60,862
24-05-14 3.17 +23.59% 54,708
24-05-13 2.565 -3.21% 11,336
24-05-10 2.65 +1.03% 6,650
24-05-09 2.623 -0.64% 11,335

Delayed Quote Nasdaq, May 15, 2024 at 04:30 pm EDT

More quotes

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Sector
Pharmaceuticals
Calendar
2024-05-19 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for CASI Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.27 USD
Average target price
6 USD
Spread / Average Target
+83.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CASI PHARMACEUTICALS, INC. Stock CASI Pharmaceuticals, Inc.
-54.33% 42.48M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+35.01% 709B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.51% 595B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.60% 367B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.83% 334B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 289B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.22% 239B
NOVARTIS AG Stock Novartis AG
+9.40% 211B
ROCHE HOLDING AG Stock Roche Holding AG
-3.31% 203B
AMGEN INC. Stock Amgen Inc.
+10.77% 171B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CASI Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW